Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Seres Therapeutics, Inc. - Common Stock (NQ:MCRB)

15.68 +0.13 (+0.83%)
Streaming Delayed Price Updated: 1:28 PM EST, Jan 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Seres Therapeutics, Inc. - Common Stock

News headline image
Seres Therapeutics to Present at Canaccord Genuity 42nd Annual Growth Conference
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Recap: Seres Therapeutics Q2 Earnings ↗
  Seres Therapeutics (NASDAQ:MCRB) reported its Q2 earnings results on Wednesday, August 3, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Seres Therapeutics Touts New Safety Data, Plans First FDA Approval For Microbiome Drug ↗
 
Via Benzinga
News headline image
Recap: Seres Therapeutics Q1 Earnings ↗
Seres Therapeutics (NASDAQ:MCRB) reported its Q1 earnings results on Wednesday, May 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Seres Therapeutics Ditches Its SER-301 Phase 1b Second Study In Ulcerative Colitis ↗
 
Via Benzinga
News headline image
Seres Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Earnings Preview: Seres Therapeutics ↗
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-08-03. Here's what investors need to know before the announcement. Analysts estimate that Seres... 
Via Benzinga
News headline image
Seres Therapeutics to Host Second Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2022
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Why Is Pinterest Higher By 14%? 20 Stocks Moving In Friday's Pre-Market Session ↗
Gainers United Maritime Corporation (NASDAQ: USEA) rose 55% to $3.41 in pre-market trading. United Maritime, on Tuesday, announced acquisition of four oil tankers and filed for stock offering on... 
Via Benzinga
News headline image
Roger Pomerantz And Shai Novik Say They're Racing To Change The Odds Of Cancer Treatments ↗
Cancer research has come a long way in the past few decades, pioneering treatments like chemotherapy and radiation treatments that have become essential weapons in the fight against this deadly and... 
Via Benzinga
News headline image
More Than $27 Million Bet On Seres Therapeutics? 4 Penny Stocks Insiders are Buying ↗
U.S. stock futures traded lower this morning on Friday ahead of jobs report for june. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Pfizer/BioNTech Ink New COVID-19 Vaccine Supply Pact, Sanofi Hit By FDA Clinical Hold, Angion Biomedica Halts Second Kidney Disease Trial ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
Seres Therapeutics Announces $100 Million Registered Direct Offering of Common Stock
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers ABVC BioPharma (NASDAQ:ABVC) shares increased by 12.3% to $1.03 during Wednesday's after-market session. The company's market cap stands at $33.2 million. 
Via Benzinga
News headline image
79 Biggest Movers From Yesterday ↗
Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 154.7% to settle at $12.10 on Tuesday on continued strength after the FDA granted clearance for the company's pūrgo technology, classifying it... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Seres Therapeutics Announces Confirmatory Results from Investigational Microbiome Therapeutic SER-109 ECOSPOR IV Open-Label Study in Recurrent C. Difficile Infection
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Presents Microbiome Therapeutic Research at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Presents Phase Ill Results of SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Seres Therapeutics Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Seres Therapeutics (NASDAQ:MCRB) reported Q1 sales of $1.49 million. Earnings fell to a loss of $56.62 million, resulting in a 13.25% decrease from last quarter. 
Via Benzinga
News headline image
Seres Therapeutics to Present Data on Investigational Microbiome Therapeutic SER-109 for Recurrent C. Difficile Infection at the Digestive Disease Week (DDW) Annual Meeting
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
The Daily Biotech Pulse: Kezar Life's Lead Asset Fails, Brickell Biotech Offloads Late-Stage Asset, Connect Biopharma Ulcerative Colitis Trial Disappoints ↗
Here's a roundup of top developments in the biotech space over the last 24 hours. 
Via Benzinga
News headline image
Seres Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
Preview: Seres Therapeutics's Earnings ↗
Seres Therapeutics (NASDAQ:MCRB) is set to give its latest quarterly earnings report on Wednesday, 2022-05-04. Here's what investors need to know before the announcement. Analysts estimate that Seres... 
Via Benzinga
News headline image
How To Attend Seres Therapeutics Q1 2022 Earnings Conference Call ↗
Seres Therapeutics (NASDAQ:MCRB) will host a conference call at 08:30 AM ET on May 4, 2022, to discuss Q1 2022 earnings results. 
Via Benzinga
News headline image
Seres Therapeutics to Host First Quarter 2022 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2022
From Seres Therapeutics, Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
Seres Therapeutics' SER-155 Reduces Infection, GvHD In Animal Study ↗
Seres Therapeutics Inc (NASDAQ: MCRB) will present preclinical findings at the European Bone Marrow Transplantation (EBMT) Annual Meeting. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.